Abstract: A method of in vitro fertilization wherein the embryo is implanted into the uterus of a female patient at least two, and preferably three to twelve months after the eggs are retrieved from the patient in order to reduce the effect of autoimmune rejection of the embryo by the patient's autoimmune system and increase the probability and success of pregnancy and wherein prior to embryo implantation, the endometrium in the uterus is prepared for embryo implantation by introducing peripheral blood mononuclear cells (PBMCs) into the uterus. The procedure is combined with cryopreservation techniques to preserve the oocytes or the IVF-produced embryos of the patient.
Type:
Grant
Filed:
October 18, 2012
Date of Patent:
April 30, 2019
Assignee:
MEZADATA MEDICAL IP HOLDING LLC
Inventors:
Alexander Feskov, Irina Feskova, Ievgeniia Zhylkova, Stanislav Zhilkov
Abstract: A method of in vitro fertilization wherein the embryo is implanted into the uterus of a female patient at least two, and preferably three to twelve months after the eggs are retrieved from the patient in order to reduce the effect of autoimmune rejection of the embryo by the patient's autoimmune system and increase the probability and success of pregnancy and wherein prior to embryo implantation, the endometrium in the uterus is prepared for embryo implantation by introducing peripheral blood mononuclear cells (PBMCs) into the uterus. The procedure is combined with cryopreservation techniques to preserve the oocytes or the IVF-produced embryos of the patient.
Type:
Application
Filed:
October 15, 2018
Publication date:
April 18, 2019
Applicant:
MEZADATA MEDICAL IP HOLDING LLC
Inventors:
Alexander Feskov, Irina Feskova, Ievgeniia Zhylkova, Stanislav Zhilkov